You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

advanced breast cancer

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Shanghai (SHR-A1811, TROP2 ADC)

Active, not recruiting
  • Breast Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 11, 2023

Breast Cancer, Treatment Side Effects, Advanced Breast Cancer Trial in Shanghai (Tumor Infiltrating Lymphocytes (TIL))

Recruiting
  • Breast Cancer
  • +3 more
  • Tumor Infiltrating Lymphocytes (TIL)
  • Shanghai, China
    Shanghai Tenth People's Hospital
Dec 19, 2022

Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Metastatic Breast Cancer Trial in Zhengzhou (SHR-A1811, Pyrotinib, Bevacizumab)

Not yet recruiting
  • Metastatic Breast Cancer
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Mar 13, 2023

Advanced Breast Cancer, Breast Tumor Malignant Female Trial in Guangzhou (AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells)

Completed
  • Advanced Breast Cancer
  • Breast Neoplasm Malignant Female
  • AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Apr 11, 2023

Breast Cancer, Advanced Breast Cancer Trial in Stanford (Talazoparib Tosylate)

Not yet recruiting
  • Breast Cancer
  • Advanced Breast Cancer
  • Talazoparib Tosylate
  • Stanford, California
    Stanford University
Nov 9, 2022

PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer Trial (RLY-5836, Fulvestrant, Palbociclib)

Not yet recruiting
  • PIK3CA Mutation
  • +7 more
  • (no location specified)
Mar 7, 2023

Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer Trial in Guangzhou (Fluzoparib, Fluzoparib+Camrelizumab)

Recruiting
  • Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
  • Guangzhou, Guangdong, China
    Sun-yat sen university cancer center
Jan 27, 2023

Inetetamab Combined With Pyrotinib and Vinorelbine in ABC

Recruiting
  • HER2-positive Advanced Breast Cancer
  • Inetetamab Combined With Pyrotinib and Vinorelbine
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 3, 2023

CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast

Not yet recruiting
  • Breast Cancer
  • CDK4/6 inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023

Advanced Breast Cancer Trial in Shijia Zhuang (SYHX2011, Paclitaxel for injection (albumin-bound))

Not yet recruiting
  • Advanced Breast Cancer
  • SYHX2011
  • Paclitaxel for injection (albumin-bound)
  • Shijia Zhuang, Hebei, China
    The Fourth Hospital of Hebei Medical University
Feb 22, 2023

Breast Cancer, Advanced Breast Cancer Trial in Shanghai (Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and

Not yet recruiting
  • Breast Cancer
  • Advanced Breast Cancer
  • Everolimus 10 mg
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 14, 2023

HER2-positive Advanced Breast Cancer Patients Treated With ADC

Recruiting
  • Breast Cancer
  • HER2 expression of circulating tumor cells
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Apr 18, 2023

HER2-low Advanced Breast Cancer Patients Treated With ADC

Recruiting
  • Breast Cancer
  • HER2 expression of circulating tumor cells
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Apr 18, 2023

Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage I Trial in Shanghai (FWD1802, palbocilib)

Recruiting
  • Metastatic Breast Cancer
  • +3 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 26, 2023

HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and

Not yet recruiting
  • HER2+ Advanced Breast Cancer
  • Other Solid Tumors
  • ADCC-R-Epo-R T-cells + Trastuzumab
  • +2 more
  • (no location specified)
Aug 31, 2023

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Recruiting
  • Breast Neoplasm
  • +4 more
  • PIK3CA inhibitor
  • +12 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023

Trastuzumab Emtansine as Therapy in Chinese HER2 Positive

Not yet recruiting
  • Breast Cancer
  • Trastuzumab emtansine
  • (no location specified)
Jul 13, 2023

ER+ HER2- Advanced Breast Cancer Trial in Chuo-ku, Kashiwa, Koto-ku (AZD9833)

Active, not recruiting
  • ER+ HER2- Advanced Breast Cancer
  • Chuo-ku, Japan
  • +2 more
Jan 24, 2023

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)

Not yet recruiting
  • Advanced HR+ HER2 Negative Breast Carcinoma
  • (CDK)4/6 inhibitor
  • (no location specified)
Sep 27, 2022

Advanced Breast Cancer Trial in Changsha (TQB3909 tablets)

Recruiting
  • Advanced Breast Cancer
  • TQB3909 tablets
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Mar 16, 2023

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

Not yet recruiting
  • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
  • PERT-IJS plus trastuzumab, carboplatin and docetaxel
  • Perjeta plus trastuzumab, carboplatin and docetaxel
  • (no location specified)
Sep 21, 2023